Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK1 | P06493 | 13/20 | 0.63 |
| ▸ | PDGFRA | P16234 | 5/20 | 0.51 |
| ▸ | CCNE1 | P24864 | 5/20 | 0.51 |
| ▸ | CDK2 | P24941 | 5/20 | 0.51 |
| ▸ | SRC | P12931 | 1/20 | 0.50 |
| ▸ | PRKCA | P17252 | 1/20 | 0.48 |
| ▸ | FLT3 | P36888 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6574935 | 1.00 | CDK1 (0.63) | CDK1PDGFRACCNE1CDK2SRC | |
| SCHEMBL6576293 | 0.92 | CDK1 (0.68) | CDK1PDGFRACCNE1CDK2SRC | |
| SCHEMBL6576280 | 0.92 | CDK1 (0.68) | CDK1PDGFRACCNE1CDK2SRC | |
| SCHEMBL6574768 | 0.89 | CDK1 (0.71) | CDK1PDGFRACCNE1CDK2SRC | |
| SCHEMBL6574771 | 0.89 | CDK1 (0.71) | CDK1PDGFRACCNE1CDK2SRC | |
| SCHEMBL6574942 | 0.88 | CDK1 (0.67) | CDK1PDGFRACCNE1CDK2SRC | |
| SCHEMBL6574939 | 0.88 | CDK1 (0.67) | CDK1PDGFRACCNE1CDK2SRC | |
| SCHEMBL6576078 | 0.88 | CDK1 (0.69) | CDK1PDGFRACCNE1CDK2SRC | |
| SCHEMBL6574923 | 0.88 | CDK1 (0.69) | CDK1PDGFRACCNE1CDK2SRC | |
| SCHEMBL6574795 | 0.87 | CDK1 (0.68) | CDK1PDGFRACCNE1CDK2SRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6767906-B2 | INHIBIT P34CDC2/CYCLIN BCDC13 KINASE AND PROTEIN TYROSINE KINASE PP60C-SRC AND CAN BE USED FOR TREATMENT OF HYPERPROLIFERATIVE DISEASES, FOR EXAMPLE CHEMOTHERAPY OF TUMOURS OR OSTEOPOROSIS. | NOVARTIS AG (CH) | 2004-07-27 | — | — | US | claimed |
| EP-1153024-B1 | 2-AMINO-6-ANILINO-PURINES AND THEIR USE AS MEDICAMENTS | NOVARTIS AG (CH) | 2004-04-28 | — | — | EP | claimed |
| US-20020016329-A1 | 2-Amino-6-anilino-purines and their use as medicaments | NOVARTIS AG (CH) | 2002-02-07 | — | — | US | claimed |
| EP-1153024-B1 | 2-AMINO-6-ANILINO-PURINES AND THEIR USE AS MEDICAMENTS | NOVARTIS AG (CH) | 2004-04-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020016329-A1 | 2-Amino-6-anilino-purines and their use as medicaments | CDK14, CDK1, CCNB1 | CDK1 2/4885PDGFRA 2503/4885CCNE1 30/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.